NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech delivered with its better-than-expected Q4 2024 results. Cambridge, ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday ...

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox ...

Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($GOLD) ), ( ($INTU) ), ( ($NTLA) ) and ( ($BYON) ). Here is a ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and strategic restructuring.

NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...